Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0601 for on-demand treatment of bleeding in adult hemophilia with inhibitors
CTR20240597Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemiltenase alfa in hemophilia A and hemophilia B (HB), sponsored by Staidson Biopharmaceutical. Primary endpoint: 12-hour effective hemostasis rate. Started Feb 2024; status: completed.
02
Drugs
bemiltenase alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20240597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240597.